Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer.
Karachaliou
N
N
Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece.
Saloustros
E
E
Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece.
Vamvakas
L
L
Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece.
Mavroudis
D
D
Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece.
Georgoulias
V
V
Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece. Electronic address: georgsec@med.uoc.gr.
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use*; D011507:Proteinuria / Q000139:chemically induced*; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D000068258:Bevacizumab; D017239:Paclitaxel